RETRACTED: Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy

Baik, Hyun-Man; Choe, Bo-Young; Son, Byung-chul; Jeun, Sin‐Soo; Kim, Moon-Chan; Lee, Kwang Soo; Kim, Bum Soo; Lee, Jae-Mun; Lee, Hyoung-Koo; Suh, T

doi:10.1016/s0720-048x(02)00211-5

Cited by 16 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the Cho/Cr values showed difference with a p value of 0.03. The ratios computed with the RBFNN also compared favorably with those reported in literature [41][42][43][44][45]. The slight variations in the area ratios between published and our (RBFNN and LF) values are expected, since our values are averaged over all voxels covering different brain tissue types within the VOI whereas the published values are based on single voxel measurements.…”

Section: Human Brain Data-supporting

confidence: 77%

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Bhat

Sajja

Narayana

2006

Journal of Magnetic Resonance

View full text Add to dashboard Cite

Accurate quantification of the MRSI-observed regional distribution of metabolites involves relatively long processing times. This is particularly true in dealing with large amount of data that is typically acquired in multi-center clinical studies. To significantly shorten the processing time, an artificial neural network (ANN) based approach was explored for quantifying the phase corrected (as opposed to magnitude) spectra. Specifically, in these studies radial basis function neural network (RBFNN) was used. This method was tested on simulated and normal human brain data acquired at 3T. The N-acetyl aspartate (NAA)/ creatine (Cr), choline (Cho)/Cr, Glutamate + Glutamine (Glx)/Cr, and Myo-inositol (mI)/Cr ratios in normal subjects were compared with the line fitting (LF) technique and jMRUI-AMARES analysis, and published values. The average NAA/Cr, Cho/Cr, Glx/Cr and mI/Cr ratios in normal controls were found to be 1.58 ± 0.13, 0.9 ± 0.08, 0.7 ± 0.17 and 0.42 ± 0.07 respectively. The corresponding ratios using the LF and jMRUI-AMARES methods were 1.6 ± 0.11, 0.95 ± 0.08, 0.78 ± 0.18, 0.49 ± 0.1 and 1.61 ± 0.15, 0.78 ± 0.07, 0.61 ± 0.18, 0.42 ± 0.13 respectively. These results agree with those published in literature. Bland-Altman analysis indicated an excellent agreement and minimal bias between the results obtained with RBFNN and other methods. The computational time for the current method was 15 seconds compared to approximately 10 minutes for the LF-based analysis.

show abstract

Section: Human Brain Data-supporting

confidence: 77%

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Bhat

Sajja

Narayana

2006

Journal of Magnetic Resonance

View full text Add to dashboard Cite

show abstract

“…Such measurements allowed quantitative analysis of neuroprotective events that follow adoptive transfer of Cop-1 immune cells. Previous studies using single-voxel 1 H MRSI showed reduced NAA/Cho ratios in the SN and thalamus of PD patients that were reversed after successful stereotactic thalamotomy, a procedure used to control symptoms in medically intractable PD (Baik et al, 2003). MRSI analysis of the striatum has yielded inconsistent results.…”

Section: Discussionmentioning

confidence: 99%

“…Its use as a diagnostic test for PD has been hampered by the inability of previous tests to precisely localize it to the SNpc, a necessary prerequisite because of the exacting relationship of NAA to neuronal injury and the requirement for high-field MRSI to ensure precise quantitative measurements (Clarke et al, 1997;Cruz et al, 1997;Federico et al, 1997;Brooks, 2000;Clarke and Lowry, 2000;Firbank et al, 2002;Baik et al, 2003). Nevertheless, a number of advantages to NAA measurements are evident, including its exclusive relationship to synthesis in neuronal mitochondria and reduction in mitochondrial dysfunction (Clark, 1998;Signoretti et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

Quantitative¹H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease

Boska¹,

Lewis²,

Destache³

et al. 2005

J. Neurosci.

View full text Add to dashboard Cite

“…108 In PD patients receiving thalamotomy to control parkinsonian tremor, further reductions in NAA/choline ratios were reported in the substantia nigra after stereotaxic surgery. 140,141 Clinical improvements in motor function in the majority of patients after thalamotomy putatively arises from remote metabolic consequences beyond the lesion site.…”

Section: The Use Of Metabonomics In Development Of Therapeuticsmentioning

confidence: 99%

The application of NMR-based metabonomics in neurological disorders

Holmes

Tsang

Tabrizi

2006

NeuroRX

View full text Add to dashboard Cite

Summary: Advances in postgenomic technologies have radically changed the information output from complex biological systems, generating vast amounts of high complexity data that can be interpreted by means of chemometric and bioinformatic methods to achieve disease diagnosis and prognosis. Highresolution nuclear magnetic resonance (NMR) spectroscopy of biofluids such as plasma, cerebrospinal fluid (CSF), and urine can generate robust, interpretable metabolic fingerprints that contain latent information relating to physiological or pathological status. This technology has been successfully applied to both preclinical and clinical studies of neurodegenerative diseases such as Huntington's disease, muscular dystrophy, and cerebellar ataxia. An extension of this technology, 1 H magicangle-spinning (HRMAS) NMR spectroscopy, can be used to generate metabolic information on small intact tissue samples, providing a metabolic link between metabolic profiling of biofluids and histology. In this review we provide a summary of high-resolution NMR studies in neurodegenerative disease and explore the potential of metabonomics in evaluating disease progression with respect to therapeutic intervention.

show abstract

RETRACTED: Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy

Cited by 16 publications

References 0 publications

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Quantitative¹H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease

The application of NMR-based metabonomics in neurological disorders

Contact Info

Product

Resources

About

RETRACTED: Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy

Cited by 16 publications

References 0 publications

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks

Quantitative1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease

The application of NMR-based metabonomics in neurological disorders

Contact Info

Product

Resources

About

Quantitative¹H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease